Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% ...

The drug, amycretin, is a peptide designed to bind to and activate both the GLP-1 and amylin receptors. Novo Nordisk is developing the molecule for the treatment of obesity and type 2 diabetes ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

Novo Nordisk (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...